Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Apellis Pharmaceuticals Inc (APLS)

Apellis Pharmaceuticals Inc (APLS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,338,111
  • Shares Outstanding, K 109,865
  • Annual Sales, $ 66,560 K
  • Annual Income, $ -746,350 K
  • 60-Month Beta 1.36
  • Price/Sales 99.84
  • Price/Cash Flow N/A
  • Price/Book 19.27
Trade APLS with:

Options Overview Details

View History
  • Implied Volatility 78.16% ( -3.77%)
  • Historical Volatility 70.38%
  • IV Percentile 81%
  • IV Rank 27.83%
  • IV High 132.38% on 03/14/22
  • IV Low 57.26% on 10/20/21
  • Put/Call Vol Ratio 5.20
  • Today's Volume 2,814
  • Volume Avg (30-Day) 1,856
  • Put/Call OI Ratio 1.20
  • Today's Open Interest 46,202
  • Open Int (30-Day) 34,888

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -1.46
  • Number of Estimates 11
  • High Estimate -1.16
  • Low Estimate -1.75
  • Prior Year -2.28
  • Growth Rate Est. (year over year) +35.96%

Price Performance

See More
Period Period Low Period High Performance
1-Month
56.02 +5.50%
on 09/23/22
70.00 -15.57%
on 09/09/22
+1.09 (+1.88%)
since 09/06/22
3-Month
44.07 +34.11%
on 07/18/22
70.00 -15.57%
on 09/09/22
+11.58 (+24.37%)
since 07/06/22
52-Week
30.17 +95.89%
on 11/01/21
70.00 -15.57%
on 09/09/22
+26.25 (+79.91%)
since 10/06/21

Most Recent Stories

More News
Small-Cap Catalyst Pharma Is Among Market's Best Price Performers

Small-cap biotech Catalyst Pharmaceuticals has been outperforming the broader market amid earnings and revenue acceleration. It joined the S&P 600 last month.

SPSM : 35.81 (-0.44%)
CPRX : 12.47 (-2.12%)
CG : 27.64 (-2.44%)
APLS : 59.10 (+2.44%)
AERI : 15.16 (+0.26%)
BLTE : 28.84 (+0.17%)
VRNA : 10.41 (-1.79%)
RVNC : 30.66 (+5.11%)
Chart of the Day: Apellis Pharmaceuticals

The Chart of the Day belongs to the biomedical company Apellis Pharmaceutical (APLS) . I found the stock by sorting Barchart's Top Stocks to Buy list first by the closest to its 52 week high, then used...

APLS : 59.10 (+2.44%)
Apellis (APLS) Up More Than 60% in Past 3 Months: Here's Why

Apellis' (APLS) marketed drug, Empaveli, approved for treating paroxysmal nocturnal hemoglobinuria is driving revenues. The drug's label expansion studies also hold promise.

AZN : 54.91 (-3.21%)
APLS : 59.10 (+2.44%)
ORIC : 3.09 (+0.32%)
ACHL : 2.27 (-2.16%)
Why Is Apellis Pharmaceuticals, Inc. (APLS) Down 9.8% Since Last Earnings Report?

Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

APLS : 59.10 (+2.44%)
BHVN : 13.18 (+7.59%)
Apellis (APLS) Q2 Earnings and Sales Miss Estimates, Stock Down

Apellis' (APLS) missed earnings and sales estimates in the second quarter of 2022. Consequently, the stock declines.

AZN : 54.91 (-3.21%)
NVAX : 18.08 (-3.32%)
BEAM : 51.34 (+0.77%)
APLS : 59.10 (+2.44%)
Apellis Pharmaceuticals, Inc. (APLS) Reports Q2 Loss, Misses Revenue Estimates

Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of -2.10% and 4.90%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?...

APLS : 59.10 (+2.44%)
VBLT : 0.1700 (+1.49%)
Apellis Pharmaceuticals Reports Second Quarter 2022 Financial Results

Received U.S. FDA filing acceptance of NDA with Priority Review designation for intravitreal pegcetacoplan for treatment of geographic atrophy; PDUFA...

APLS : 59.10 (+2.44%)
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in...

APLS : 59.10 (+2.44%)
Inovio Pharmaceuticals (INO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Inovio (INO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

INO : 1.7400 (-2.79%)
APLS : 59.10 (+2.44%)
Apellis Pharmaceuticals to Host Conference Call on Aug 8, 2022 to Discuss Second Quarter 2022 Financial Results

WALTHAM, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in...

APLS : 59.10 (+2.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Apellis Pharmaceuticals, Inc. is a clinical-stage biotech focused on the development of novel therapeutics, which work through the inhibition of the complement system, specially targeting the C3 protein of the complement system to treat autoimmune and inflammatory diseases.

See More

Key Turning Points

3rd Resistance Point 63.65
2nd Resistance Point 61.82
1st Resistance Point 60.46
Last Price 59.10
1st Support Level 57.28
2nd Support Level 55.45
3rd Support Level 54.09

See More

52-Week High 70.00
Last Price 59.10
Fibonacci 61.8% 54.79
Fibonacci 50% 50.09
Fibonacci 38.2% 45.39
52-Week Low 30.17

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar